The treatment of factor VIII inhibitors - A general overview

Vox Sanguinis

Volumn 70, Issue SUPPL. 1, 1996, Pages 19-23

  White, Gilbert C ^a   Roberts, Harold R ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; PEPTIDE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

CONFERENCE PAPER; DRUG MEGADOSE; HEMOPHILIA A; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; SWINE;

EID: 0030020810     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000462137     Document Type: Conference Paper

References (10)

1. Brackmann HH: Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984;150.181
2. Sultan Y, White GC, Aronstam A, Bosser C, Brackmann HH, Brochier G, Gormsen J, Mariani G, Roberts HR, Scarabin Y, Scharrer I, Scheibel E: Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Nouv Rev Fr Hematol 1986; 28:85-89.
3. Ewing NP, Sanders NL, Dietrich SL, Kasper CK: Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988;259:65-68
4. Mauser-Bunschoten EP, Nilsson IM, Kasper CK: Immune tolerance, a 1990 approach; Lusher JM, Kessler CM (eds): in Hemophilia and von Willebrands Disease in the 1990s New York, Elsevier Science, New York, 1991, pp 265-269.
5. Nilsson IM, Berntorp E, Freiburghaus C: Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost 1993;70:56-59.
6. Sultan Y, Nydegger U, Karatchkine MD, Rossi E, Aligman M, Dietrich G: IVIgG in the treatment of patients with factor VIII inhibitors; in Aledort LM, Hoyer LW, Lusher JM, Reisner HM. White GC (eds): Proc 2nd Int Symp on Inhibitors to Coagulation Factors. New York, Plenum Publishing, 1994.
7. Telgt DSC, Macik BG, McCord DM, Monroe DM, Roberts HR: Mechanism by which recombinant factor VIIa shortens the aPTT. Activation of factor X in the absence of tissue factor. Thromb Res 1989;56:603-609.
8. Lusher JM, Shapiro SS, Plascek JE, Rao AV, Levine PH, Blatt PM Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies for factor VIII. A multicenter trial. N Engl J Med 1980,303:421-425
9. Sjamsodin LJM, von Heijnene AP, Sixma JJ: The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII: A randomized double-blind clinical trial N Engl J Med 1981;328.947-950.
10. Lollar P, Parker ET, Fay PJ: Coagulant properties of hybrid human/porcine factor VIII molecules J Biol Chem 1990;265:1688-1692